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Skina b s t r a c t
The skin is an ideal target tissue for vaccine delivery for a number of reasons. It is highly accessible, and
most importantly, enriched in professional antigen presenting cells. Possessing strong similarities to
human skin physiology and displaying a defined epidermis, the guinea pig is an appropriate model to
study epidermal delivery of vaccine. However, whilst we have characterized the humoral responses in
the guinea pig associated with skin vaccine protocols we have yet to investigate the T cell responses.
In response to this inadequacy, we developed an IFN-c ELISpot assay to characterize the cellular immune
response in the peripheral blood of guinea pigs. Using a nucleoprotein (NP) influenza pDNA vaccination
regimen, we characterized host T cell responses. After delivery of the DNA vaccine to the guinea pig epi-
dermis we detected robust and rapid T cell responses. The levels of IFN-c spot-forming units averaged
approximately 5000 per million cells after two immunizations. These responses were broad in that mul-
tiple regions across the NP antigen elicited a T cell response. Interestingly, we identified a number of NP
immunodominant T cell epitopes to be conserved across an outbred guinea pig population, a phe-
nomenon which was also observed after immunization with a RSV DNA vaccine. We believe this data
enhances our understanding of the cellular immune response elicited to a vaccine in guinea pigs, and
globally, will advance the use of this model for vaccine development, especially those targeting skin as
a delivery site.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction in the development of vaccines, including those targeting influen-The skin is an attractive site for vaccination for several reasons,
its accessibility lends itself to a less invasive and more tolerable
vaccination site, the ability to directly monitor the site, and per-
haps most importantly, the high number of resident professional
antigen presenting cell (APC) populations at this site. Multiple pre-
clinical experiments and clinical trials have demonstrated deliver-
ing a vaccine to the skin elicits robust immune responses in the
host [1–7].
Historically the guinea pig (Cavea porcellus) has been one of the
most widely used experimental animal models, so much that the
term ‘‘guinea pig” has become a popular metaphor for scientific
experimentation. The guinea pig model played an important roleza, tuberculosis, diphtheria, and viral hemorrhagic fevers [8–11].
The guinea pig played an important role in the development of
the two most widely used vaccines that are delivered at the skin,
the BCG vaccine targeting tuberculosis and the rabies vaccine
[12,13]. Unlike other small animal models such as the mouse, the
guinea pig’s skin possesses a defined epidermis, and is considered
an optimal surrogate small animal model in terms of tissue phys-
iology for preclinical vaccine studies targeting the epidermis. Fur-
thermore the Hartley guinea pig strain is outbred, endowing
further relevance on this animal as pre-clinical surrogate model
for vaccine development.
We are currently developing a skin surface electroporation
(SEP)-based platform to deliver DNA vaccines, and we have previ-
ously demonstrated the elicitation of robust humoral responses in
guinea pigs after employing this delivery platform [2,14]. However,
a limited catalogue of reagents available has hampered our ability
to characterize vaccine-induced T cell responses in this model.
Although a number of studies aimed at characterizing T cell
62 K. Schultheis et al. / Vaccine 35 (2017) 61–70responses in this important animal model have been reported [15–
19], little is known concerning the cellular immune responses
associated with skin vaccination in the guinea pig.
Here we describe the development of an IFN-c ELISpot assay to
quantify and monitor the cellular responses in a Hartley guinea pig
model. Specifically, we evaluate cellular responses during a vacci-
nation regimen with a pDNA vaccine encoding the Influenza nucle-
oprotein (PR8) delivered to the skin of guinea pigs with the SEP
device. Importantly, this assay uses peripheral blood cells so the
kinetics of the host immune response elicited in a single guinea
pig can be monitored by blood collection rather than sacrifice of
multiple animals to remove lymphoid organs as a source of respon-
der cells. We utilized this assay to characterize T cell responses eli-
cited following pDNA vaccination. We proceeded to identify
immunodominant T cell epitopes associated with responses
against Influenza and RSV antigens in the animals immunized.
Interestingly, in an outbred population of guinea pigs, all vacci-
nated animals displayed T cell responses against these epitopes.
Data gathered in this study greatly increases our understanding
of the cellular immune responses elicited by vaccination in a phys-
iological relevant pre-clinical small animal model, and will greatly
assist in expediting the translation of candidate vaccines into the
clinic.2. Materials and methods
2.1. Electroporation devices
The epidermal targeting surface EP (SEP) was an electrode array
consisting of an array of gold-plated trocar needle of 0.43 mm
diameter at a 1.5 mm spacing (Inovio Pharmaceuticals, Plymouth
Meeting, PA). The SEP array is pressed down on the skin bleb made
by Mantoux delivery of 50 ll plasmid formulation, in a manner in
which all electrodes across the array contact the skin. The elec-
trodes do not penetrate the live skin layers. Three individual
100 ms pulses of 25 V were delivered.
2.2. Animals
Female Hartley guinea pigs (8–10 weeks old) were purchased
from Charles River Laboratories (Wilmington, MA). Animals were
group housed with ad libitum access to food and water. Guinea pigs
were group housed (4 per cage) and handled at BTS Research (San
Diego, CA) according to the standards of the Institutional Animal
Care and Use Committee (IACUC).
2.3. Plasmid DNA
NP vaccine plasmid encodes the full-length nucleoprotein
derived from the A/Puerto Rico/8 (H1N1) strain of influenza.
RSV-F vaccine plasmid contained an insert which was a consensus
sequence of the RSV fusion glycoprotein of subtype A and B viruses.
Sequences for the consensus strategy were obtained from
GenBank. Consensus RSV-F was synthetically codon and RNA-
optimized and then subcloned into a modified pVAX1 mammalian
expression vector. All plasmids were diluted in 1xPBS before injec-
tion. In immunization studies 30 lg of pNP and 100 lg of pRSV-F
was delivered.
2.4. Overlapping peptide pools
The influenza A virus (A/Puerto Rico/8/34(H1N1)) nucleocapsid
protein peptide pools were created by synthesizing 120 individual
15mer peptides spanning the 498 amino acid sequence of the anti-
gen. Peptides overlapped by 11 aa creating a 4 aa shift betweennext peptide in the sequence. Peptides were split into three pools
each containing 40 individual peptides. The RSV-F peptide pool
was matched to the consensus sequence of the RSV fusion glyco-
protein of subtype A and B viruses. Peptides overlapped by 11 aa
creating a 4 aa shift between next peptide in the sequence. Pep-
tides were split into three pools each containing 20 individual
peptides.
2.5. Endpoint-binding titer ELISA
Antibody responses against influenza NP and H5HA were per-
formed as previously described [20]. Optical densities (OD) were
read at 450 nm, and determined to be a positive titer if OD was
two times that of background control. The bottom positive titer
on the plate was plotted as the end-point titer.
2.6. Guinea pig IFN-c ELISPOT assay
For the Interferon gamma ELISPOT with splenocytes, guinea
pigs were euthanized and the spleens were harvested. Spleens
were placed in 10 ml of cold PBS with 10% fetal bovine serum
(FBS) and 1% (v/v) Penicillin/Streptomycin (R10 medium). Spleens
were split in half, pummeled and passed through a 70 lm cell
strainer to achieve single cell suspensions. For the IFN-c ELISPOT
with PBMCs three milliliter peripheral blood was drawn from the
jugular vein of each anaesthetized animal and transferred immedi-
ately into EDTA blood collection tubes. Blood was diluted 1:1 with
HBSS. Diluted Blood was layered over Ficoll-Paque Plus (GE Health-
care Life Sciences) and centrifuged (2000 rpm, 30 min, 24 C).
PBMCs were resuspended at 1x106 cells/ml in R10 medium and
plated at 100 ll/well on 96-well Millipore IP plates (Millipore) pre-
viously coated with 5 lg/ml primary anti-IFN-c antibody V-E4
(antibodies for this assay were kindly provided by Dr. Schafer,
Robert Koch Institute, Berlin, Germany) blocked with 10% (w/v)
Sucrose and 2% (w/v) BSA (Sigma) in PBS. 100 ll of peptide or ConA
stimulants were added to the cells. Samples were assayed in trip-
licates. After incubation in humidified 5% CO2 at 37 C for 18 h,
cells were removed by washing and 100 ll per well of 2 lg/ml
biotinylated secondary anti-IFN-c antibody N-G3 diluted in block-
ing buffer was added. Following a 2 h incubation and washing,
alkaline phosphatase-conjugated streptavidin (R&D Systems Inc.)
was added at 100 ll per well for 1 h at room temperature. Follow-
ing washes, wells were incubated for 20 min at room temperature
with 100 ll per well of BCIP/NBT detection reagent substrate (R&D
Systems Inc.). Interferon-gamma positive spots were imaged, ana-
lyzed and counted using a CTL-Immunospot S6 ELISPOT Plate
Reader and CTL-Immunospot software.3. Results
3.1. Detection of cellular immune responses by IFN-c ELISpot following
pDNA immunization of guinea pigs
With the aim of detecting antigen-specific T cell responses in
the guinea pigs immunized with a plasmid DNA construct encod-
ing the influenza nucleoprotein from the PR8 strain (pNP), we
tested a detection and capture antibody pair – raised in mice,
and recognizing conformation-specific epitopes on guinea pig
IFN-c - in an ELISpot assay [15,21]. First, to confirm the guinea pigs
had mounted immune responses against the influenza NP antigen
following this treatment regimen we analyzed antibody binding
titers. Fig. 1a demonstrates all the pNP–immunized guinea pigs
harbored IgG antibodies reactive to NP antigen (mean endpoint
binding titer of 1:28,350). To determine whether these animals
harbored antigen-specific T cell responses we sacrificed the guinea
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Fig. 1. Development of an IFN-c ELISpot to detect cellular immune responses after pDNA immunization of guinea pigs. Hartley guinea pigs were immunized with 30 lg of a
pDNA vaccine encoding the nucleoprotein of Influenza virus PR8 (pNP). Anti-Influenza PR8 nucleoprotein binding titers were detected in the serum of pNP immunized guinea
pigs by ELISA (a). Splenocytes were stimulated overnight with peptide pools 1–3 spanning the NP antigen in wells coated with guinea pig anti-IFN-c capture antibody. Spots
forming units were detected after peptide and Con A stimulation using splenocytes isolated from a guinea pig immunized with pNP (b). Enumeration of IFN-c spot forming
units (SFU) for a pNP immunized (c) and non-treated (d) guinea pig. The average SFU’s for each pool in the pNP immunized group versus the non-treated group is displayed
(e). Mean SFU’s ±SD are plotted. Three guinea pigs in the pNP group and two in the non-treated group. Data representative of two independent experiments.
K. Schultheis et al. / Vaccine 35 (2017) 61–70 63pigs, harvested their spleens and single cell suspensions were pre-
pared. Splenocytes from individual guinea pigs were added to ELI-
Spot plates coated with the IFN-c capture antibody, and stimulated
overnight with peptide pools containing 15mer peptides (overlap-
ping by 11 amino acids), and spanning the entire Influenza NP PR8
protein encoded by the pNP vaccine. The peptides were split into
three pools (as described in methods section). Representative
visual images of IFN-c spot forming units (SFU’s) in wells contain-
ing non-stimulated, NP peptide Pool 1- or ConA-stimulated spleno-
cytes from a pNP-vaccinated guinea pig are shown in Fig. 1b. An
example enumeration of the IFN-c ELISpot response in splenocytes
harvested from a vaccinated animal (Fig. 1c) and a non-vaccinated
animal (Fig. 1d) is shown. The IFN-c response to peptides in Pool 1
(group mean of 2690 SFU’s/106 cells) dominated over Pool 2
(group mean of 470 SFU’s/106 cells) and Pool 3 (group mean of
330 SFU’s/106 cells) across the vaccinated group (Fig. 1c and e).
In the non-vaccinated group the response against the NP peptide
pools was not significantly higher than background levels
(Fig. 1d and e). The cumulative mean response against Pools 1–3
spanning the entire NP antigen was 3490 SFU’s/106 cells in the
vaccinated group, compared to 240 SFU’s/106 cells in the non-
vaccinated group (Fig. 1e).
3.2. The kinetics of the cellular immune response elicited in a
vaccination regimen delivering pNP ID with surface EP
The development of an effective vaccine product requires the
ability to monitor both the immediate and long term levels of host
immunity elicited following immunization. Ideally the investigatorwould be able to monitor the kinetics of the resulting immune
response across a vaccination course in each individual animal.
Sacrificing the animal to obtain the splenocytes will limit the anal-
ysis to a snapshot of the immune response mounted in an individ-
ual at a specific moment in time. To circumvent the need to
sacrifice an animal to detect cellular immune responses, we col-
lected whole blood samples from the jugular vein, and obtained
PBMC populations by density gradient centrifugation. Collection
of 3 ml of peripheral blood yielded between 2 and 4 million PBMCs.
The antigen-specific IFN-c ELISpot responses between splenocytes
and PBMCs harvested from vaccinated animals were not signifi-
cantly different (Supplemental Fig. 1). Thus, we proceeded with
PBMCs harvested at defined time points to monitor the cellular
immune responses elicited during a vaccination regimen. This reg-
imen included the delivery of pNP vaccine to the abdominal skin of
the guinea pig enhanced by a surface electroporation device (SEP).
This EP device consists of a 4  4 array of electrodes, which makes
direct contact with surface of skin where a bleb was made by the
intradermal injection of 50 ll pDNA using the Mantoux technique
[2,14]. The electrical field produced by activating the SEP device
permits gene expression that is limited to the epidermis, and
expression of the plasmid DNA is short-lived (approx. 7 days)
due to the high turnover rate of cells in this tissue in the guinea
pig [22]. The IFN-c ELISpot responses measured during the vacci-
nation regimen are presented in Fig. 2. Fig. 2a displays the IFN-c
cellular immune response kinetics to the NP peptide Pools 1–3
for an individual guinea pig. Fig. 2b displays the average response
in a group of 5 guinea pigs. Robust IFN-c + T cell responses (700
SFU’s/106 PBMCs) were detected 14 days after the first treatment.
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Fig. 2. Robust IFN-c+ cellular immune responses are detected after delivery of pDNA vaccine to the skin with electroporation. On days 1 and 15 pNP DNA vaccine (30 lg) was
delivered to the skin immediately followed by SEP electroporation. The PBMC IFN-c ELISpot response was measured 14 days after the first immunization (prime), 7 days after
the second (boost) and 46 days after the second (memory). (a) IFN-c+ SFU’s in an individual guinea pig. (b) Mean SFU’s ±SEM are plotted for a group of 5 guinea pigs, along
with pie charts indicating the percentage of the response generated by each pool.
64 K. Schultheis et al. / Vaccine 35 (2017) 61–70On day 21, a strong boost response (4840 SFU’s/106 PBMCs) was
observed seven days after the second immunization. The memory
recall response detected at day 60 after the initial treatment was
1814 SFU’s/106 cells. The immune response against antigenic
determinants in the influenza NP protein was broad. The response
detected after the prime was focused upon peptide determinant/s
in Pool 1 (83% of the total response), however the responses were
more balanced after the boost (46% for Pool 1, 22% for Pool 2 and
31% for Pool 3) and memory time point (52% for Pool 1, 14% for
Pool 2 and 34% for Pool 3). In summary, we detected strong and
broad cellular immune responses to be elicited against influenza
NP antigen after ID delivery of a pNP vaccine with SEP.
3.3. Influenza NP T cell epitope mapping
With the goal to further characterize the cellular immune
response elicited in guinea pigs we aimed to identify MHC class Iand MHC class II-presented epitopes recognized by CD8 and CD4
T cells, respectively. Due to the limits of blood draw (survival bleed
not to exceed 10% of total circulating blood – as recommended by
the Joint Working Group on Refinement, 1993) we could not har-
vest a sufficient number of PBMCs to analyze the responses to
the total of 120 individual peptides in Pools 1, 2 and 3. We chose
to analyze the IFN-c responses to the individual peptides only in
influenza NP peptide Pool 1 in pNP-vaccinated guinea pigs. Peptide
Pool 1 was selected because approximately 50% of the total
response (IFN-c SFUs) to influenza NP PR8 antigen after pNP vacci-
nation was to peptide determinant/s in this pool (Fig. 2). This sug-
gested important T cell epitopes resided in this pool.
From animals which previously received two doses of the pNP
vaccine delivered ID with SEP, PBMCs were harvested and stimu-
lated with the 20 individual 15mer overlapping (4 aa shifts) pep-
tides in Pool 1. These peptides spanned the first 175 aa of the NP
PR8 antigen. Fig. 3a depicts the IFN-c ELISpot response of an indi-
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Fig. 3. Antigenic peptide determinant mapping of the IFN-c response after pNP
immunization. PBMCs were harvested from non-treated or guinea pigs immunized
with pNP, and plated into 42 wells. The PBMCs in wells 1–40 were stimulated as
indicated with one of the individual 15mer peptides that span the influenza NP
antigen Pool 1 region, cells in well 41 were not stimulated and well 42 were
stimulated with ConA. (a) The enumeration of PBMC IFN-c SFU’s recorded against
each NP Pool 1 peptide from a pNP immunized, and (b) from a non-treated guinea
pig is depicted. (c) IFN-c SFU’s from each pNP immunized guinea pig plotted. Mean
SFU ±SEM against each peptide is displayed.
K. Schultheis et al. / Vaccine 35 (2017) 61–70 65vidual pNP-immunized guinea pig. Responses were observed
against peptides 8 and 9 (2160 and 2160 SFU’s/106 cells, respec-
tively), and peptide 15 (2440 SFU’s/106 cells). No responses were
observed in untreated guinea pigs (Fig. 3b). In all pNP-
immunized animals we observed responses against peptides 8
and 9, ranging between 500 and 3360 with a mean of 1533
SFU’s/106 cells for peptide 8, and ranging between 800 and 3540with a mean of 1690 SFU’s/106 cells for peptide 9 (Fig. 3c). Addi-
tionally, all pNP-immunized animals responded to peptide 15,
ranging between 500 and 2900 with a mean of 1730 SFU’s/106 cells
(Fig. 3c).
Fig. 3 displays the levels of IFN-c SFUs after stimulation with
the adjacent peptides [8,9] to be equivalent (1533 and 1690
SFU’s/106, respectively), suggesting a shared epitope to be present
in the overlapping region between the peptides. The length of this
shared region was 11 aa. To identify this T cell epitope we trun-
cated the 11mer from the N- and C-terminal, and stimulated
PBMCs from a non-treated (Fig. 4a) and pNP-immunized (Fig. 4b)
animal. All tested truncated versions of the IGGIGRFYIQM 11mer
elicited IFN-c SFUs of similar magnitude, except the 8mer
IGRFYIQMwhich failed to elicit a detectable response (Fig. 4b). This
finding was observed in all the pNP-immunized guinea pigs tested
(Fig. 4c). Thus, peptide truncation analysis identified the 6mer
GIGRFY to be an immunodominant epitope in the influenza NP
PR8 antigen. The size of this epitope suggests a MHC class I
determinant.
Similar analysis of truncated versions of peptide 15 was per-
formed to determine the associated T cell epitope (Fig. 5). No
IFN-c SFUs significantly above background were detected after
stimulation of PBMCs form pNP-immunized animals with trun-
cated versions of peptide 15 (Fig. 5a–c). Thus identifying the
15mer IQNSLTIERMVLSAF as the minimal determinant stimulating
the IFN-c response. MHC class II molecules generally present epi-
topes between 12 and 16 aa’s in length. This data strongly suggests
this epitope to be a MHC II determinant recognized by CD4 + T
cells.3.4. Respiratory syncytial virus (RSV) F T cell epitope mapping
Our findings with the influenza NP PR8 antigen suggested the
same immunodominant epitopes within the virus-associated anti-
gen may be targeted across the outbred Hartley guinea pig popula-
tion. To test the generality of these findings to other respiratory
viruses for which we lack an effective vaccine, we analyzed the
IFN-c cellular immune responses to peptides within the respira-
tory syncytial virus (RSV) F protein after immunization with a
pDNA vaccine encoding the RSV fusion protein (F). Responses
against peptides in RSV F overlapping peptide library Pool 1 was
chosen, as data suggested that determinant/s within this pool eli-
cited the major portion of the detectable IFN-c ELISpot response
in guinea pigs vaccinated with a plasmid encoding the RSV F anti-
gen (see suppl. Fig. 2). Guinea pigs were treated with one dose of
pRSV F delivered ID with SEP. Analysis of the IFN-c ELISpot
responses against the individual 15mer overlapping peptides [1–
20] which span Pool 1 of the RSV F antigen revealed an immun-
odominant T cell epitope was residing within peptide number 20
(Fig. 6a and c). The response to this peptide in non-treated animals
was not above background (Fig. 6b). All pRSV F-immunized ani-
mals responded to peptide 20, the mean response of the six guinea
pigs was 360 SFU’s/106 cells, with a range of 170–800 SFU’s/106
cells (Fig. 6c). In summary, the results indicate the T cell responses
driven by pDNA vaccines encoding respiratory disease virus associ-
ated antigens RSV F and influenza NP, are focused upon a limited
number of immunodominant determinants in outbred Hartley gui-
nea pigs.4. Discussion
The induction of robust T cell responses has been described as
essential to vaccine efficacy in many disease settings including,
HIV, Influenza, Ebola and cancer [23]. As such the ability to assay
and monitor these responses is critical to the vaccine development
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Fig. 4. T cell epitope mapping of an immunodominant 6mer determinant after pNP immunization. The 11mer overlapping region shared between NP peptides 8 and 9 was
truncated. In an IFN-c ELISpot PBMCs from (a) non-treated and (b and c) pNP immunized guinea pigs were stimulated with the truncated peptide epitopes. IFN-c SFU’s were
enumerated for a non-treated (a), a pNP immunized guinea pig (b). The responses from the three pNP immunized guinea pigs assayed are depicted in (c), with the mean SFU
±SD against each peptide displayed. Data indicated GIGRFY to be the immunodominant epitope.
66 K. Schultheis et al. / Vaccine 35 (2017) 61–70pathway. Here we describe a novel protocol for the assessment of
cellular responses through an IFN-c ELISPot in a guinea pig model.
We believe this to be first example of a non-terminal approach to
the assessment of vaccine-elicited T cell responses in guinea pigs.
The guinea pig possesses skin of a similar thickness and struc-
ture to that of human skin, and is thus considered an optimal sur-
rogate small animal model for vaccine delivery studies where the
dermal compartment is the target for the vaccine delivery
[24,25]. However, currently there is a paucity in tools to detect
and characterize cellular immune responses in this animal. Here,to our knowledge for the first time, we report an IFN-c ELISpot
assay that can be used to detect T cell cellular responses to vaccine
associated antigens in the peripheral blood. Specifically, we ana-
lyzed the kinetics of the cellular immune responses elicited follow-
ing EP-enhanced pDNA delivery into the skin.
pDNA vaccination strategies offer significant advantages over
the conventional attenuated or inactivated vaccines. pDNA vacci-
nes have an excellent safety profile, can be manufactured to a large
scale quickly, are easy to formulate, and can elicit both humoral
and cellular responses. Importantly, DNA vaccines can be designed
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Fig. 5. T cell epitope mapping of an immunodominant 15mer determinant after pNP immunization. Truncated amino acid sequences of the peptide number 15 in NP peptide
Pool 1 were synthesized. In an IFN-c ELISpot PBMCs from (a) non-treated and (b and c) pNP immunized guinea pigs were stimulated with the truncated peptide epitopes. IFN-
c SFU’s were enumerated for a non-treated (a), a pNP immunized guinea pig (b). The responses from all three of the pNP guinea pigs are depicted in (c) with the mean SFU ±SD
against each peptide displayed. Data indicated IQNSLTIERMVLSAF to be the immunodominant epitope.
K. Schultheis et al. / Vaccine 35 (2017) 61–70 67to express single or multiple target antigens of choice in a single
formulation. However, the ability to efficiently deliver pDNA vacci-
nes has been problematic, and was historically cited as the major
reason for the low immune potency of this treatment in higher
species [26]. As such, considerable effort has been attached to
the development of enhanced delivery technologies to improve
the uptake of pDNA in vivo in higher order animals. Delivery tech-
niques, including electroporation [2,6,27,28], gene gun [29,30], tat-
tooing [1,31] and microneedles [32], have been developed to
reliably enhance gene expression in the skin tissue. The electropo-ration (EP) platform is a physical technique based on applying brief
electrical pulses to the tissue of choice. Under the correct
conditions this leads to cell membrane opening in a transient
and reversible manner, facilitating the direct transport of pDNA
into the cell. Upon comparison to naked DNA vaccination, a 10–
100 fold enhancement of the immunological response was
observed when EP was employed as an enabling delivery technol-
ogy [33–35]. While intramuscular (IM) EP has historically been the
target tissue of choice, recently, considerable effort has been
employed to develop intradermal (ID) EP techniques toward
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Fig. 6. Identification of an immunodominant antigenic peptide determinant in guinea pigs immunized with pRSV-F. PBMCs were harvested from non-treated or guinea pigs
after immunization with pRSV-F, and plated into 22 wells. The PBMCs in first 20 wells stimulated one of the individual 15mer peptides that span the RSV-F antigen Pool 1
region, cells in well 21 were not stimulated and in well 22 were stimulated with ConA. (a) The enumeration of PBMC IFN-c SFU’s recorded against each RSV-F Pool 1 peptide
from a pRSV-F immunized, and (b) from a non-treated guinea pig is depicted. (c) IFN-c SFU’s the six pRSV-F immunized guinea pigs are plotted. Mean SFU ±SEM against each
peptide is displayed.
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bined with the low penetration depths required for effective drug
delivery, result in a less invasive and therefore potentially more
tolerable clinical procedure [36,38]. The high number of resident
professional antigen presenting cell populations endow the skin
with very attractive characteristics for a target tissue for vaccine
delivery. Multiple preclinical experiments and clinical trials have
demonstrated that vaccinating in the skin elicits robust immune
responses [1–7]. We have used both the intradermal invasive
(CELLECTRA-3P) and a surface (SEP) EP platforms to significantlyenhance the expression of reporter gene plasmid in the skin and
induce robust immunity [2,14,20,39,40]. While cellular responses
in the dermally relevant non-human primate model can be easily
assayed following immunization, the use of this model for vaccine
screening protocols is limited due to the associated costs and avail-
ability of these species. The mouse is another model where the
host cellular response is routinely monitored. However, the murine
model lacks the relevant translation of skin physiology which lim-
its its use for dermal vaccination protocols. Therefore, a greater
insight of the cellular immune responses elicited following skin
K. Schultheis et al. / Vaccine 35 (2017) 61–70 69pDNA delivery enhanced by EP in a dermally clinically relevant
small animal model, such as the guinea pig was needed. Here,
we delineate for the first time the peripheral cellular immune
responses driven by pDNA vaccination of the skin in the guinea
pig. The ability to do this will greatly facilitate vaccine develop-
ment studies based upon antigen delivery to the skin.
The results we gathered in this study concerning the magnitude
of T cell responses in the guinea pig after skin vaccination were
very encouraging. The magnitude of the T cell immune response
to NP antigen was 4840 IFN-c + SFU’s/106 PBMCs after second
immunization. Furthermore, 14 days after one dose of pNP we
observed levels averaging 700 IFN-c SFU’s/106 PBMCs, suggesting
we were eliciting robust immune responses early in our immu-
nization regimen. This observation is in line with previous skin
vaccination studies by our group and others [1,14]. Our previous
studies have demonstrated the specific delivery of pDNA into the
epidermis permits the direct transfection of resident Langerhans
cells. Further investigation delineated a mechanism via which
motile guinea pig epidermal Langerhans cells expressing pDNA
delivered by SEP, rapidly migrate out of the skin to the draining
lymph nodes where they prime an adaptive immune response
[14]. The ability to now monitor T cell and antibody responses in
a more relevant pre-clinical surrogate model will significantly aide
us in a more complete understanding of the character of the
immune response elicited by our vaccine and how it correlates
with disease protection. Future studies have been designed to
determine whether delivery of pDNA vaccine with SEP provides
early protection against influenza and Ebola virus challenge in
pre-clinical models such as the guinea pig. Positive results will
strengthen our case for an ID-delivered DNA vaccine as a suitable
strategy to rapidly target emerging disease threats for example
influenza pandemics, Ebola or MERS outbreaks. Importantly, pro-
tection of guinea pigs from Ebola challenge after skin vaccination
with a DNA vaccine delivered with EP was recently reported [9].
Preliminary investigations of vaccination regimens in guinea pigs
with Ebola DNA vaccines are showing very strong and rapid T cell
responses (data not shown). Most importantly, we recently
observed robust immune responses elicited to Ebola DNA vaccine
delivered ID in humans (manuscript in preparation).
One very interesting observation we made in this study was the
recognition of a limited number of conserved T cell epitopes across
a group of outbred animals. These observations support the similar
findings reported by Gillis et al. after vaccination of an outbred
group of guinea pigs with CMV [15]. In our study, separate vaccina-
tion protocols delivering two different respiratory viral disease
DNA vaccines, Influenza and RSV, suggested a number of immun-
odominant epitopes were eliciting T cell responses. Epitope map-
ping analysis after pNP influenza immunization revealed two
dominant epitopes to be present in the nucleoprotein 1–175 aa
region of the NP PR8 antigen. The size of the identified epitopes
strongly suggested a MHC class II epitope (IQNSLTIERMVLSAF)
stimulating a CD4 + T cell response and a MHC class I epitope
(GIGRFY) driving a CD8 + T cell response. However, we have not
functionally confirmed these epitopes to be classical MHC class I
or II-restricted. Thus we cannot rule out the possibility of these
epitopes being associated with non-classical MHC molecules, such
as class-Ib, which may present a less diverse repertoire of peptides
and target more broad populations of CD8 + T cells [41]. Currently
there is limited evidence that class Ib-restricted contribute to viral
immunity. However, H2-M3-restricted CD8 + T cells have been
induced after influenza virus stimulation [42,43], but their ability
to kill virally infected cells has yet to be demonstrated. Further-
more, Hansen and colleagues recently reported broadly targeted
CD8 + T cell responses restricted by MHC Ib molecule E in non-
human primates immunized with a SIV-targeting vaccine [44].
Although it remains out of the scope of this study to further deter-mine the role of MHC in guinea pig T cell immunity, our observa-
tions and those by others should prompt further investigations
[15].
In conclusion, we have described the use of a novel assay sys-
tem to greatly enhance our ability detect and understand the cel-
lular immune response in the very relevant, but underused, pre-
clinical guinea pig model for skin vaccine development. We believe
this study resulting in a working protocol will aide in the advance-
ment of the guinea pig as tool for vaccine development. By utilizing
the described IFN-c ELISpot assay we have gained the ability to
refine our skin vaccination research efforts in a highly relevant sur-
rogate model without the need to sacrifice the animal. Finally, we
have highlighted the ability of pDNA vaccines delivered to the epi-
dermis of the skin, with a non-invasive EP device to drive high
magnitude T cell responses.
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